Back to News

By Herb Newborg

H1N1 (Swine Flu) Vaccine Only Works in One in Four Recipients
Three in four vaccine recipients WILL NOT be protected from H1N1 infection, package inserts reveal.

The H1N1 influenza vaccine industry has a dirty little secret that no one is talking about. The following statement is included in the FDA approved package insert of the Influenza A (H1N1) 2009 Monovalent Vaccine, manufactured by CSL Limited and approved for use in the U.S.:

“Specific levels of HI antibody titers post-vaccination with inactivated influenza virus vaccine have not been correlated with protection from influenza virus. In some human studies, antibody titers of 1:40 or greater have been associated with protection from influenza illness in up to 50% of subjects.”

In plain English, this means that the vaccine only works in 50% or less of those individuals that attain an acceptable level of “seroconverison” after vaccination.

The FDA defines seroconversion as achieving an “antibody titer” of 1:40. IF the vaccine was 100% effective at achieving “seroconverison”, it would provide protection in up to 50% of recipients.

But the vaccines are not 100% effective at achieving seroconversion.

The only vaccine approved in the U.S. which includes efficacy data on the package insert is the Influenza A (H1N1) 2009 Monovalent Vaccine from CSL Limited. They state that their vaccine only provides seroconversion for a dismal 48% of those 18-65 and only 34% for those over 65.

This means the vaccine works, at best, in only 1 in 4 recipients (48% of 50%). Not very encouraging odds.

Three in four vaccine recipients WILL NOT be protected from H1N1 infection. This is the likely reason why doctors and other health care workers who know the facts are choosing not to expose their families to the risk of a novel, barely tested vaccine with such a slim chance of any benefit.

One more damning statement from the package insert:

“Neither Influenza A (H1N1) 2009 Monovalent Vaccine nor AFLURIA has been evaluated for carcinogenic or mutagenic potential or for impairment of fertility.”

So the vaccine works, at best, in one in four recipients. It has not been tested to rule out the potential to cause cancer or infertility. Is this a risk worth taking to avoid the much hyped swine flu? Let us look at the numbers.

In 99.999% of Americans who contract the H1N1 virus, the body does exactly what it is supposed to do naturally and without any chemical intervention.

The body develops mild symptoms as a result of the infection, then produces natural antibodies and one quickly returns to health with natural, lasting protection against any future recurrence of the infection.

The vaccine may provide some resistance to H1N1 infection in less than 25% of the recipients, for some undefined period of time.

Cancer, infertility and who knows what other side effects for a 25% chance of some limited protection or a 99.999% chance of dealing with the virus naturally, with lasting protection and no deadly side effects.

Who do you trust, your body or your favorite multinational drug company (who have legal immunity for any damages you may incur)?

You don’t need to be a math major to solve that equation.